96-week CASTLE data show similar efficacy results.
出版信息
AIDS Patient Care STDS. 2008 Nov;22(11):918.
PMID:19043840
Abstract
摘要
相似文献
1
96-week CASTLE data show similar efficacy results.
AIDS Patient Care STDS. 2008 Nov;22(11):918.
2
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66.
3
[New treatment options for HIV-infected patients].
Dtsch Med Wochenschr. 2004 May 7;129(19):1093.
4
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int. 2009 Jun;18(101):104.
5
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
MMW Fortschr Med. 2009 Apr 30;151(18):35.
6
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
J Infect. 2011 Apr;62(4):319-21. doi: 10.1016/j.jinf.2011.02.004. Epub 2011 Feb 15.
7
CASTLE study showed similar efficacy.
AIDS Patient Care STDS. 2008 Mar;22(3):253.
8
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med. 2003 Dec 11;145(50):61.
9
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Antivir Ther. 2011;16(3):339-48. doi: 10.3851/IMP1745.
10
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
HIV Med. 2011 Jul;12(6):374-82. doi: 10.1111/j.1468-1293.2011.00917.x. Epub 2011 Apr 24.
Zotero 插件